Capecitabine
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Naga P. ChalasaniSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bis-Octanoyl -1,3-Butanediol Washington University School of Medicine | Phase 2 | CCC |
Same molecule, other indications
Capecitabine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →